Zhenzhen Xu

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 6

Top Topics

Acute Myeloid Leukemia

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Statistics in medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Poornima Sharma, Yvette L Kasamon, Xue Lin, Zhenzhen Xu, Marc R Theoret, Tejashri Purohit-Sheth
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Zhenzhen Xu, Bin Zhu, Yongsoek Park
Design for immuno-oncology clinical trials enrolling both responders and nonresponders. Statistics in medicine 39 (27) (2020)
Zhenzhen Xu, Yongsoek Park, Boguang Zhen, Bin Zhu
Designing cancer immunotherapy trials with random treatment time-lag effect. Statistics in medicine 37 (30) (2018)